DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV)

Publication Authors:

Bridgette Franey, Michael Grimm, Dae Young Lee, Jiyoon Jeong, Mi-Kyung Kim, Marcus Hompesch

Presented at the European Association for the Study of Diabetes (EASD) meeting, September 2021.

About

DA-1241 is a novel small molecule selective GPR119 agonist. In preclinical studies DA-1241 enhanced insulin and GLP-1 secretion, reduced glucose excursions, lowered blood glucose and improved dyslipidemia. The primary objective of Part 1 of this study was to assess the safety and tolerability of multiple once daily oral doses of DA-1241 compared to placebo in HV. Secondary objective was to estimate the plasma pharmacokinetic (PK) characteristics.

VIEW
DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV) thumbnail